US64131A1051 - Common Stock - After market: 3.47 +0.29 (+9.12%)
NASDAQ:STIM (9/30/2022, 7:00:01 PM)+0.27 (+9.28%)
|GICS Sector||Health Care|
|GICS Industry||Health Care Equipment & Supplies|
|Earnings (Last)||08-02 2022-08-02/bmo||Earnings (Next)||11-07 2022-11-07|
|Ins Owners||8.17%||Inst Owners||68.85%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 184 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
31 General Warren Blvd.
Malvern PENNSYLVANIA 19355
CEO: Keith J. Sullivan
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to faster patient identification of those in need...
The state-of-the-art training center is the first of its kind to further best practices with transformative NeuroStar Advanced Therapy for Mental Health...
Latest NeuroStar innovation to simplify the motor threshold determination for clinicians...
MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing,...
Here you can normally see the latest stock twits on STIM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.